News – Page 926 – Endpoints News

AstraZeneca challenges Roche on frontline SCLC after seizing an interim win — and Merck may not be far behind

6 years ago

Transparency: FDA to release more info on premarket reviews

6 years ago

Sanofi/Regeneron muscle ahead of a rival Novartis/Roche team, win first approval in key rhinosinusitis field

6 years ago

Two biotech unicorns swell proposed IPOs, eyeing a $600M-plus windfall

6 years ago

Vesalius gets to work on €120M Fund III — expect more on women's health, oncology

6 years ago

Novartis holds back the copycat brigade's attack on its top drug franchise — for now

6 years ago

Oxford Biomedica, Santen ink gene therapy pact; DayTwo raises $31M in Series B round

6 years ago

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

6 years ago

While Akorn works to revive its fortunes, the FDA hits it with another warning letter

6 years ago

After raising $158M, this upstart's founders have star backers and plans to break new ground in gene therapy

6 years ago

Rare disease player rakes in a meaty $81M in Spain's biggest ever private biotech fundraise

6 years ago

Arch-backed ImmusanT scraps PhII as celiac therapy flops in a key test

6 years ago

Chris Varma unveils MPM's latest startup — eyeing 'undruggable' cancer targets and powered by machine learning, ...

6 years ago

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to ...

6 years ago

SQZ, Erytech kick off $57M cell therapy partnership; Jean-Paul Kress lands new CEO gig at MorphoSys

6 years ago

FDA rejects Acer's rare disease drug, asks for new trial — shares crater

6 years ago

Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?

6 years ago

AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash

6 years ago

Aldeyra's eye drug fails pivotal test in patients with rare, inflammatory disease

6 years ago

With 4 more biotech IPOs due to wrap up Q2, how is the class of 2019 faring?

6 years ago

Eyeing a $500M peak sales pot, Almirall doubles down on lebrikizumab as Dermira lines up PhIII

6 years ago

AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts

6 years ago

GSK/Tesaro PARP inhibitor Zejula wins another speedy review

6 years ago

Suffering Novartis partner Conatus grabs the ax and packs it in on NASH after a series of setbacks

6 years ago

First page Previous page 923 924 925926927 928 929 Next page Last page